Investigational Alzheimer’s drug slows rate of cognitive decline, study suggests

Researchers found that after two years of treatment on diranersen, participants demonstrated a 54% reduction in cognitive decline on the Alzheimer’s Disease Assessment Scale–Cognitive Subscale.
An older woman receives an injection in her upper arm

An investigational Alzheimer’s drug reduced the rate of decline in some cognitive functions by more than half, according to phase II trial results.

The findings of the global CELIA trial, which were presented at the Clinical Trials on Alzheimer’s Disease conference, held in Boston, Massachusetts, on 16–19 November 2026, revealed that at the two-year mark, treatment with diranersen (Biogen) resulted in a 54% reduction in cognitive decline as measured by the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog), compared with a placebo.

Diranersen is an antisense oligonucleotide therapy, which targets the tau protein and is given as a twice-yearly injection. The trial included 60 participants who took diranersen and 115 people who took placebo.

Researchers also observed a 38% reduction in cognitive decline on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) scale among participants who took diranersen.

In a statement published on 17 November 2026, Priya Singhal, executive vice president and head of development at Biogen, said: “These findings strengthen the growing body of evidence supporting tau as a therapeutic target and underscore the potential of diranersen to meaningfully impact disease progression for people living with early Alzheimer’s disease.”

Richard Oakley, associate director for research and innovation at the Alzheimer’s Society, told The Pharmaceutical Journal on 19 November 2026: “Alzheimer’s is a complex disease, but we know that the build-up of two proteins in the brain, amyloid and tau, play an important role in its development.

“While many recent scientific advances have focused on amyloid, we urgently need treatments that tackle Alzheimer’s [disease] in different ways. Diranersen is a particularly interesting therapy because it targets tau at its source.

“It works a bit like a gene ‘off-switch’, reducing the amount of tau the brain produces rather than trying to clear it once it has already built up. The treatment is given via lumbar puncture into the fluid around the spinal cord.”

Oakley also noted that the latest results “are very encouraging”, adding that “they suggest that diranersen effectively reduces the build up of tau in the brain, and the treatment’s ability to slow worsening of memory and thinking problems increases over two years”.

“If these promising findings are confirmed in the upcoming phase III trial, a significant new treatment option for early Alzheimer’s disease could be within touching distance,” he continued.

Sheona Scales, director of research at Alzheimer’s Research UK, also said that the findings were “encouraging”, adding that they “suggest that benefits may build over time, raising the exciting possibility that targeting tau could have an increasing impact on slowing disease progression”.

“While exciting, these longer-term results come from an open-label extension, where participants and researchers know which treatment is being given. A larger phase III trial will be essential to confirm whether diranersen is effective, establish the best dose and better understand its safety,” she said.

“For people affected by Alzheimer’s [disease], treatments that can slow the progression of the disease in a clinically meaningful way could make a real difference to people’s lives.”

The findings come shortly after the Medicines and Healthcare products Regulatory Agency (MHRA) awarded an innovation passport to diranersen on 9 November 2026.

This development means that research into the diranersen can be supported through the MHRA’s  innovative licensing and access pathway. The pathway is intended to “de-risk product development and accelerate patient access to transformative new medicines and drug–device combinations, by providing a single integrated platform for collaboration”, the MHRA said.

Responding to the MHRA’s decision, Kylie Bromley, managing director for Biogen UK and Ireland, said: “We now have an opportunity to collaborate with partners across the health system to ensure that innovations reach the patients who need them. This achievement reinforces our optimism for the future of innovation in Alzheimer’s disease.”

Last updated
Citation
The Pharmaceutical Journal, PJ November 2026, Vol 317, No 8015;317(8015)::DOI:10.1211/PJ.2026.1.439519

    Please leave a comment 

    You may also be interested in